Výsledky vyhledávání - "Tomoya Funamoto"

Akademický článek

Severe Drug-Induced Interstitial Lung Disease After Administration of Osimertinib as Adjuvant Treatment for Resected EGFR-Mutated NSCLC: A Case Report

Autor: Sho Mitsuya, MD, Masahiro Arai, MD, Kiyoe Kanaoka, MD, Tomoya Funamoto, MD, Hiroyuki Tsuji, MD, Kenjiro Tsuruoka, MD, PhD, Ninso Matsunaga, MD, Takahiko Nakamura, MD, Yosuke Tamura, MD, PhD, Masafumi Imanishi, MD, PhD, Soichiro Ikeda, MD, PhD, Akihisa Imagawa, MD, PhD, Yasuhito Fujisaka, MD, PhD

Publikováno v: JTO Clinical and Research Reports, Vol 5, Iss 2, Pp 100631- (2024)

Osimertinib administration has been approved as an adjuvant treatment after complete surgical resection in patients with EGFR-mutated NSCLC. This article presents the first report of life-threatening postoperative osimertinib-induced interstitial lun

Externí odkaz: https://doaj.org/article/26d3d531b4c84fe79dd21d8013090533

Zobrazit plný text záznamu

Comparison Between Second- and Third-generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors as First-line Treatment in Patients With Non-small-cell Lung Cancer: A Retrospective Analysis

Autor: Takahiko Nakamura, Kenjiro Tsuruoka, Kiyoe Kanaoka, Yosuke Tamura, Yasuhito Fujisaka, Soichiro Ikeda, Tomoya Funamoto, Masafumi Imanishi, Isao Goto, Akihisa Imagawa, Hiroyuki Tsuji, Sho Mitsuya, Ninso Matsunaga

Publikováno v: Anticancer Research. 41:5137-5145

BACKGROUND For epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC), administration of EGFR tyrosine kinase inhibitors (TKIs) is mandatory to prolong survival. To date, a comparison of second- and third-generation EGFR-T

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1fa4700940c7a872dbc66ac9176a43fc
https://doi.org/10.21873/anticanres.15331

Zobrazit plný text záznamu

Osimertinib is associated with reversible and dose-independent cancer therapy-related cardiac dysfunction

Autor: Kazumi Nishino, Hayato Kawachi, Toru Kumagai, Yoshihiro Miyashita, Hanako Kuhara, Satoshi Oizumi, Motohiro Tamiya, Kei Kunimasa, Risa Kamada, Takashi Matsunaga, Satoshi Hara, Toru Oka, Noriyuki Yamada, Masashi Fujita, Tomoya Funamoto, Takahisa Kawamura, Takako Inoue, Fumio Imamura

Publikováno v: Lung cancer (Amsterdam, Netherlands). 153

The use of osimertinib is associated with the risk of cancer therapy-related cardiac dysfunction (CTRCD) for EGFR-mutated non-small cell lung cancer (NSCLC) patients. In this study, we aimed to clarify the clinical features of patients with CTRCD ass

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::260800e966f8378633d35eab4ff38174
https://pubmed.ncbi.nlm.nih.gov/33468320

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání